Fagron NV (LON:0HNZ)

Market Cap	1.16B
Revenue (ttm)	723.47M
Net Income (ttm)	66.62M
Shares Out	n/a
EPS (ttm)	0.91
PE Ratio	17.43
Forward PE	n/a
Dividend	0.18 (0.90%)
Ex-Dividend Date	May 21, 2024

Volume	1,623
Average Volume	2,413
Open	19.32
Previous Close	19.38
Day's Range	19.14 - 19.48
52-Week Range	13.10 - 16.47
Beta	0.32
RSI	51.98
Earnings Date	Feb 20, 2025

About Fagron NV

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. It operates in three segments: Essentials, Brands, and Compounding Services. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. Its products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders; Pentravan use...

• Industry: Medical, Dental, and Hospital Equipment and Supplies
• Founded: 1990
• Employees: 3,282
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0HNZ

Financial Performance

In 2024, Fagron NV's revenue was 874.84 million, an increase of 14.66% compared to the previous year's 762.99 million. Earnings were 80.55 million, an increase of 14.18%.

Financial numbers in EUR